One hundred million treatments of Artemether-Lumefantrine Dispersible, an antimalarial developed especially for children with P. falciparum malaria, have been delivered by Novartis to 35 malaria-endemic countries. Artemether-Lumefantrine Dispersible is the product of the partnership between MMV and Novartis. It is the first WHO prequalified child-friendly artemisinin-combination therapy (ACT) and addresses an unmet need for paediatric medicines.